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Linezolid has good activity against staphylococci and enterococci,inhibiting themajority of strains at concentrations between 1 and
4 g/ml (1, 2). The susceptibility breakpoint for Enterococcus spp. is
fixed by the European Committee on Antimicrobial Susceptibility
Testing at 4 g/ml (http://www.eucast.org/fileadmin/src/media
/PDFs/EUCAST_files/Breakpoint_tables) and by the Clinical and
Laboratory Standards Institute at2g/ml (3).
The data in the literature suggest that, to obtain clinical success
in the treatment of serious infections, the plasma linezolid con-
centration should remain above the MIC of the causative organ-
ism for more than 85% of the time over 24 h (4). Concerns have
been expressed byMorata et al., who recently documented a wide
interpatient variability in linezolid pharmacokinetic parameters
in intensive care unit (ICU) patients (5).
We report the case of a breakthrough bacteremia during lin-
ezolid therapy, caused by a susceptible Enterococcus faecalis in a
critically ill patient.
A previously healthy 21-year-old Caucasian male (body mass
index, 21.6 kg/m2), was admitted in the general ICU following a
car accident polytrauma (score of 6 on the Glasgow coma scale).
A computed tomography scan revealed acute subdural hema-
toma, brain edema, and multiple fractures of the skull base. On
day 1, the hematoma was evacuated, and a drainage was placed in
the subdural space. Ceftriaxone (2,000mg every 24 h) was admin-
istered from day 1 to day 8. On day 12, the patient presented
hypothermia (35.3°C) and leukocytosis (white blood cell count,
20,530/l) with neutrophilia (84%). An empirical intravenous
treatment with linezolid (600 mg every 12 h) plus meropenem
(1,000 mg every 8 h) was started, considering the possibility of a
central nervous system infection by contiguity. Linezolid was ad-
ministered intravenously (i.v.) over a 30-min period, at 1:00 a.m.
and 1:00 p.m. Cultures of blood, urine, and bronchoalveolar la-
vage specimens, taken before the beginning of antibiotic treat-
ment, yielded negative results. On day 15, the patient presented
a rapid increase in body temperature (maximum 39.7°C) associ-
ated with an increased procalcitonin value (1.35 ng/ml), and an
E. faecalis was isolated from blood culture. Identification and
susceptibility testing were performed by matrix-assisted laser de-
sorption ionization–time of flight mass spectrometry (Vitek MS,
bioMérieux, Marcy l’Etoile, France) and the reference broth mi-
crodilution method, respectively (6). The isolate was susceptible
to vancomycin (MIC, 2 g/ml), ampicillin (MIC, 2 g/ml), and
linezolid (MIC, 2 g/ml) and high-level resistant to gentamicin
(MIC, 128 g/ml). Cultures from the central venous catheter
and urine and cerebrospinal fluid samples were negative. The an-
tibiotic regimen was changed when identification of the blood
isolatewas available (onday 16), and the infectionwas successfully
treated with 14 days of i.v. vancomycin (2,000 mg every 24 h in a
continuous infusion) and meropenem (1,000 mg every 8 h).
Blood samples obtained on days 15 and 16, after 4 and 5 days of
the start of linezolid, respectively, were analyzed for quantification
of linezolid using high-performance liquid chromatography
(HPLC). Plasma linezolid concentrations were determined by
HPLC assay, with UV absorbance detection of 254 nm. The limit
of quantification was 0.06 g/ml. The intra-assay precision was
94%, and the interassay precision at 0.5 g/ml was90%. The
correlation between drug concentration and area value was good
for both aqueous and serum samples across the concentration
range (r2, 0.995 for both) (7).
Samples were obtained at 7:00 a.m., 6 h since the last adminis-
tration. The two concentrations were 1.47 and 2.13g/ml, respec-
tively. Therefore, plasma linezolid levels were lower than theMIC
from 7:00 a.m. to 1:00 p.m. of day 15 (50%of the time in 24 h) and
for an approximately similar period after 7:00 a. m. of day 16,
meaning almost 50% of the time in 24 h. The patient had normal
renal function (estimated glomerular filtration, 121ml/min), liver
function, and plasma protein values, and no concomitant drug
interacting with linezolid was administered. No other features of
the patient or of his medical conditions could be identified that
could explain the low plasma linezolid values.
These findings underscore how standard dosing of linezolid
could be inefficient in prevention of bacteremia caused by Entero-
coccus spp. with MIC values of 2 g/ml, which correspond ap-
proximately to 45% of Enterococcus faecalis and 60% of wild-type
Enterococcus faecium isolates (http://mic.eucast.org/Eucast2/).
Furthermore, under these circumstances, exposure to subop-
timal drug concentration could play a role in the development of
linezolid-resistant mutants.
The opportunity to perform therapeutic drug monitoring
(TDM) for optimization of linezolid dose should be considered in
similar cases. Where TDM is not applicable, a loading dose or
continuous infusion should be considered to improve the efficacy
of linezolid treatment (7, 8).
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